TAK-755-4007: A Post-Authorization Safety Study (PASS) to Further Evaluate Real-World Safety in Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated with Adzynma

14/01/2026
10/06/2026
EU PAS number:
EUPAS1000000870
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

TAK-755-4007-clinical-study-protocol-redact.pdf

English (1.54 MB - PDF) View document
Study results
Study report
Other information